Los Angeles Capital Management LLC Buys Shares of 27,889 Arvinas, Inc. (NASDAQ:ARVN)

Los Angeles Capital Management LLC purchased a new position in Arvinas, Inc. (NASDAQ:ARVN) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 27,889 shares of the company’s stock, valued at approximately $1,148,000. Los Angeles Capital Management LLC owned 0.05% of Arvinas at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ARVN. China Universal Asset Management Co. Ltd. boosted its position in shares of Arvinas by 96.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,374 shares of the company’s stock valued at $27,000 after acquiring an additional 674 shares during the period. Sectoral Asset Management Inc. raised its position in shares of Arvinas by 13.5% in the third quarter. Sectoral Asset Management Inc. now owns 7,010 shares of the company’s stock worth $138,000 after buying an additional 835 shares in the last quarter. Swiss National Bank boosted its stake in Arvinas by 1.2% during the third quarter. Swiss National Bank now owns 99,700 shares of the company’s stock valued at $1,958,000 after buying an additional 1,200 shares during the period. Harbor Capital Advisors Inc. grew its position in Arvinas by 7.3% during the fourth quarter. Harbor Capital Advisors Inc. now owns 18,167 shares of the company’s stock worth $748,000 after buying an additional 1,239 shares in the last quarter. Finally, Exchange Traded Concepts LLC increased its stake in Arvinas by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 5,746 shares of the company’s stock worth $237,000 after acquiring an additional 1,457 shares during the last quarter. 95.19% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. BMO Capital Markets boosted their price objective on Arvinas from $89.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, February 28th. Citigroup downgraded shares of Arvinas from a “buy” rating to a “neutral” rating and lifted their price objective for the stock from $36.00 to $55.00 in a report on Wednesday, February 14th. The Goldman Sachs Group started coverage on Arvinas in a research note on Thursday, February 1st. They issued a “buy” rating and a $70.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $87.00 price target on shares of Arvinas in a research note on Wednesday. Finally, Barclays increased their price objective on Arvinas from $26.00 to $60.00 and gave the company an “overweight” rating in a research report on Thursday, February 29th. Two investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $61.33.

Arvinas Stock Down 5.7 %

Shares of NASDAQ ARVN opened at $32.37 on Thursday. The company has a market cap of $2.21 billion, a price-to-earnings ratio of -4.98 and a beta of 1.95. The firm’s fifty day moving average is $39.00 and its 200 day moving average is $35.55. Arvinas, Inc. has a 52 week low of $13.57 and a 52 week high of $53.08.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.45. The firm had revenue of $25.30 million during the quarter, compared to the consensus estimate of $32.94 million. Arvinas had a negative net margin of 185.09% and a negative return on equity of 70.24%. The company’s quarterly revenue was down 22.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.54) earnings per share. Equities research analysts anticipate that Arvinas, Inc. will post -5.02 earnings per share for the current year.

Insider Buying and Selling at Arvinas

In other news, CFO Sean A. Cassidy sold 1,702 shares of Arvinas stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $47.05, for a total value of $80,079.10. Following the sale, the chief financial officer now directly owns 181,916 shares in the company, valued at approximately $8,559,147.80. The sale was disclosed in a filing with the SEC, which is available through this link. In other Arvinas news, CFO Sean A. Cassidy sold 1,702 shares of the company’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $47.05, for a total value of $80,079.10. Following the completion of the transaction, the chief financial officer now directly owns 181,916 shares in the company, valued at approximately $8,559,147.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Ronald Peck sold 1,699 shares of Arvinas stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $47.05, for a total transaction of $79,937.95. Following the sale, the insider now directly owns 67,516 shares in the company, valued at approximately $3,176,627.80. The disclosure for this sale can be found here. Insiders sold 8,597 shares of company stock valued at $404,489 in the last 90 days. Insiders own 5.23% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.